中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 6
Jun.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(6): 1213-1219

Mechanism of action of immune molecules and related immune cells in liver failure

DOI: 10.12449/JCH250632
  • 1.

    Graduate School of Guangxi University of Chinese Medicine，Nanning 530200，China

  • 2.

    Department of Hepatology，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China

Research funding:

Regional Joint Fund Project of National Natural Science Foundation of China (U23A20521);

Yao Chun Gui School of Traditional Chinese Medicine Masters Inheritance Workshop (GZY2024002);

Guangxi Traditional Chinese Medicine Diagnosis and Treatment of Difficult and Serious Diseases Research Team (2022A001);

Guangxi Major Special Project of Science and Technology (GuiKe AA23023035);

Advantageous Disease Liver Failure - Traditional Chinese Medicine Retention and Enema Technique for the Treatment of Liver Failure/Hepatic Encephalopathy Standardised Research (2023019-03)

More Information
  • Corresponding author: FU Lei， lfu@gxtcmu.edu.cn （ORCID： 0009-0001-1600-3068）; YAO Chun， yaoc@gxtcmu.edu.cn （ORCID： 0000-0003-2903-8814）
  • Received Date: 2024-10-20
  • Accepted Date: 2024-11-13
  • Published Date: 2025-06-25
    Abstract
  • Liver failure （LF） is a severe clinical syndrome characterized by severe impairment or decompensation of liver function. At present， the key role of immune molecules in the pathogenesis of LF has been well established. These molecules not only directly participate in the pathological process of LF， but also influence the course of LF by modulating the behavior of immune cells. In addition， immune molecules can be used as potential biomarkers for evaluating the prognosis of LF. This article summarizes the role of immune molecules in LF and explores the therapeutic strategies based on these immune molecules， in order to provide new directions for the diagnosis and treatment of LF.

     

    • FullText(HTML)
  • loading
    • References(44)
  • [1]
    TAFESH ZH, SALCEDO RO, PYRSOPOULOS NT. Classification and epidemiologic aspects of acute-on-chronic liver failure[J]. Clin Liver Dis, 2023, 27( 3): 553- 562. DOI: 10.1016/j.cld.2023.03.002.
    [2]
    SHAH S, GOLDBERG DS. Acute-on-chronic liver failure: Update on pathogenesis, therapeutic targets, predictive models, and liver transplantation[J]. Curr Opin Gastroenterol, 2021, 37( 3): 173- 178. DOI: 10.1097/MOG.0000000000000722.
    [3]
    DĄBROWSKA A, WILCZYŃSKI B, MASTALERZ J, et al. The impact of liver failure on the immune system[J]. Int J Mol Sci, 2024, 25( 17): 9522. DOI: 10.3390/ijms25179522.
    [4]
    FUJIMOTO Y, KUWAMURA M, AZUMA YT. Deficiency of interleukin-19 exacerbates lipopolysaccharide/D-galactosamine-induced acute liver failure[J]. J Vet Med Sci, 2020, 82( 10): 1450- 1455. DOI: 10.1292/jvms.20-0344.
    [5]
    LI L, CHEN L, LIN F, et al. Study of the expression of inflammatory factors IL-4, IL-6, IL-10, and IL-17 in liver failure complicated by coagulation dysfunction and sepsis[J]. J Inflamm Res, 2021, 14: 1447- 1453. DOI: 10.2147/JIR.S302975.
    [6]
    WEI HY, YI K, LI FF, et al. Multimodal tetrahedral DNA nanoplatform for surprisingly rapid and significant treatment of acute liver failure[J]. Adv Mater, 2024, 36( 30): e2305826. DOI: 10.1002/adma.202305826.
    [7]
    ZHAO SM, JIANG JH, JING YY, et al. The concentration of tumor necrosis factor-α determines its protective or damaging effect on liver injury by regulating Yap activity[J]. Cell Death Dis, 2020, 11( 1): 70. DOI: 10.1038/s41419-020-2264-z.
    [8]
    XIE H, ZENG JY, YAN X, et al. Clinical significance and properties of IFN-γ+IL-17+Th17 cells in liver injury associated with chronic hepatitis B virus infection[J]. Digestion, 2022, 103( 6): 438- 450. DOI: 10.1159/000526924.
    [9]
    FU S, NI TZ, ZHANG MM, et al. Cholinergic anti-inflammatory pathway attenuates acute liver failure through inhibiting MAdCAM1/α4β7-mediated gut-derived proinflammatory lymphocytes accumulation[J]. Cell Mol Gastroenterol Hepatol, 2024, 17( 2): 199- 217. DOI: 10.1016/j.jcmgh.2023.10.012.
    [10]
    TANG YL, ZHU L, TAO Y, et al. Role of targeting TLR4 signaling axis in liver-related diseases[J]. Pathol Res Pract, 2023, 244: 154410. DOI: 10.1016/j.prp.2023.154410.
    [11]
    ENGELMANN C, SHEIKH M, SHARMA S, et al. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure[J]. J Hepatol, 2020, 73( 1): 102- 112. DOI: 10.1016/j.jhep.2020.01.011.
    [12]
    LI WY, ZHANG WB, ZHANG DM, et al. Effect of lipopolysaccharide on TAK1-mediated hepatocyte PANoptosis through Toll-like receptor 4 during acute liver failure[J]. Int Immunopharmacol, 2024, 129: 111612. DOI: 10.1016/j.intimp.2024.111612.
    [13]
    SAYAF K, BATTISTELLA S, RUSSO FP. NLRP3 inflammasome in acute and chronic liver diseases[J]. Int J Mol Sci, 2024, 25( 8): 4537. DOI: 10.3390/ijms25084537.
    [14]
    ZHANG W, TAO SS, WANG T, et al. NLRP3 is dispensable for d-galactosamine/lipopolysaccharide-induced acute liver failure[J]. Biochem Biophys Res Commun, 2020, 533( 4): 1184- 1190. DOI: 10.1016/j.bbrc.2020.10.003.
    [15]
    LI ZH, JIANG JN. The NLRP3 inflammasome mediates liver failure by activating procaspase-1 and pro-IL-1 β and regulating downstream CD40-CD40L signaling[J]. J Int Med Res, 2021, 49( 9): 3000605211036845. DOI: 10.1177/03000605211036845.
    [16]
    ZHANG X, HU YY, WANG W, et al. IRGM/Irgm1 increases autophagy to inhibit activation of NLRP3 inflammasome in inflammatory injury induced acute liver failure[J]. Cell Death Discov, 2024, 10( 1): 272. DOI: 10.1038/s41420-024-02052-w.
    [17]
    COMERFORD I, MCCOLL SR. Atypical chemokine receptors in the immune system[J]. Nat Rev Immunol, 2024, 24: 753- 769. DOI: 10.1038/s41577-024-01025-5.
    [18]
    LI H, ZHAO XK, CHENG YJ, et al. Gasdermin D-mediated hepatocyte pyroptosis expands inflammatory responses that aggravate acute liver failure by upregulating monocyte chemotactic protein 1/CC chemokine receptor-2 to recruit macrophages[J]. World J Gastroenterol, 2019, 25( 44): 6527- 6540. DOI: 10.3748/wjg.v25.i44.6527.
    [19]
    SUN F, WANG JW, JI XF, et al. CCL25 contributes to the pathogenesis of D-Gal/LPS-induced acute liver failure[J]. J Gastroenterol Hepatol, 2024, 39( 12): 2880- 2891. DOI: 10.1111/jgh.16732.
    [20]
    DAN X, OUYANG S. The role and mechanisms of macrophage polarization and hepatocyte pyroptosis in acute liver failure[J]. Front Immunol, 2023, 14: 1279264. DOI: 10.3389/fimmu.2023.1279264.
    [21]
    JI XF, FAN YC, SUN F, et al. Noncanonical Wnt5a/JNK signaling contributes to the development of D-gal/LPS-induced acute liver failure[J]. Inflammation, 2022, 45( 3): 1362- 1373. DOI: 10.1007/s10753-022-01627-y.
    [22]
    KONG XR, LIU W, ZHANG XW, et al. HIF-1α inhibition in macrophages preserves acute liver failure by reducing IL-1β production[J]. FASEB J, 2023, 37( 9): e23140. DOI: 10.1096/fj.202300428RR.
    [23]
    BAO SX, ZHENG WY, YAN R, et al. miRNA-21 promotes the progression of acute liver failure via the KLF6/autophagy/IL-23 signaling pathway[J]. Mol Med Rep, 2024, 29( 5): 80. DOI: 10.3892/mmr.2024.13205.
    [24]
    LIU YH, ZHU L, ZHANG ZW, et al. C-C chemokine receptor 5 is essential for conventional NK cell trafficking and liver injury in a murine hepatitis virus-induced fulminant hepatic failure model[J]. J Transl Med, 2023, 21( 1): 865. DOI: 10.1186/s12967-023-04665-8.
    [25]
    ALI AK, KOMAL AK, ALMUTAIRI SM, et al. Natural killer cell-derived IL-10 prevents liver damage during sustained murine cytomegalovirus infection[J]. Front Immunol, 2019, 10: 2688. DOI: 10.3389/fimmu.2019.02688.
    [26]
    YANG LL, ZHANG Q, SONG J, et al. Interleukin-35 suppresses CD8+ T cell activity in patients with viral hepatitis-induced acute-on-chronic liver failure[J]. Dig Dis Sci, 2020, 65( 12): 3614- 3623. DOI: 10.1007/s10620-020-06077-w.
    [27]
    YU WH, LAN XQ, CAI J, et al. Critical role of IL-1β in the pathogenesis of Agrocybe aegerita galectin-induced liver injury through recruiting T cell to liver[J]. Biochem Biophys Res Commun, 2020, 521( 2): 449- 456. DOI: 10.1016/j.bbrc.2019.10.087.
    [28]
    DU B, TENG J, YIN R, et al. Increased circulating t follicular helper cells induced via il-12/21 in patients with acute on chronic hepatitis B liver failure[J]. Front Immunol, 2021, 12: 641362. DOI: 10.3389/fimmu.2021.641362.
    [29]
    WU H, GUO CQ, LIU Z, et al. Neutrophils exacerbate acetaminophen-induced liver injury by producing cytotoxic interferon-γ[J]. Int Immunopharmacol, 2023, 123: 110734. DOI: 10.1016/j.intimp.2023.110734.
    [30]
    XU L, YANG Y, JIANG JL, et al. Eosinophils protect against acetaminophen-induced liver injury through cyclooxygenase-mediated IL-4/IL-13 production[J]. Hepatology, 2023, 77( 2): 456- 465. DOI: 10.1002/hep.32609.
    [31]
    ZHU BB, GAO FY, LI YX, et al. Serum cytokine and chemokine profiles and disease prognosis in hepatitis B virus-related acute-on-chronic liver failure[J]. Front Immunol, 2023, 14: 1133656. DOI: 10.3389/fimmu.2023.1133656.
    [32]
    MURAKAMI S, IMAMURA M, UCHIDA T, et al. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure[J]. Hepatol Int, 2023, 17( 5): 1225- 1232. DOI: 10.1007/s12072-023-10532-x.
    [33]
    UMBAUGH DS, NGUYEN NT, CURRY SC, et al. The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure[J]. Hepatology, 2024, 79( 6): 1352- 1364. DOI: 10.1097/HEP.0000000000000665.
    [34]
    YANG P, ZENG YM, YANG F, et al. Transmembrane TNF-α as a novel biomarker for the diagnosis of cytokine storms in a mouse model of multiple organ failure[J]. Inflammation, 2023, 46( 1): 359- 369. DOI: 10.1007/s10753-022-01738-6.
    [35]
    ZHANG EL, HUANG JB, WANG K, et al. Pterostilbene protects against lipopolysaccharide/D-galactosamine-induced acute liver failure by upregulating the Nrf2 pathway and inhibiting NF-κB, MAPK, and NLRP3 inflammasome activation[J]. J Med Food, 2020, 23( 9): 952- 960. DOI: 10.1089/jmf.2019.4647.
    [36]
    WANG FZ, GONG SH, WANG T, et al. Soyasaponin II protects against acute liver failure through diminishing YB-1 phosphorylation and Nlrp3-inflammasome priming in mice[J]. Theranostics, 2020, 10( 6): 2714- 2726. DOI: 10.7150/thno.40128.
    [37]
    MOHAMADI-ZARCH SM, BALUCHNEJADMOJARAD T, NOURABADI D, et al. Esculetin alleviates acute liver failure following lipopolysaccharide/D-galactosamine in male C57BL/6 mice[J]. Iran J Med Sci, 2021, 46( 5): 373- 382. DOI: 10.30476/ijms.2020.84909.1474.
    [38]
    MA J, XU Y, ZHANG M, et al. Geraniol ameliorates acute liver failure induced by lipopolysaccharide/D-galactosamine via regulating macrophage polarization and NLRP3 inflammasome activation by PPAR-γ methylation Geraniol alleviates acute liver failure[J]. Biochem Pharmacol, 2023, 210: 115467. DOI: 10.1016/j.bcp.2023.115467.
    [39]
    WANG X, SUN YP, LI PX, et al. The protective effects of myricetin against acute liver failure via inhibiting inflammation and regulating oxidative stress via Nrf2 signaling[J]. Nat Prod Res, 2023, 37( 5): 798- 802. DOI: 10.1080/14786419.2022.2089138.
    [40]
    ZHAO X, YIN F, FU LQ, et al. Garlic-derived exosome-like nanovesicles as a hepatoprotective agent alleviating acute liver failure by inhibiting CCR2/CCR5 signaling and inflammation[J]. Biomater Adv, 2023, 154: 213592. DOI: 10.1016/j.bioadv.2023.213592.
    [41]
    ZHAO X, YIN F, HUANG YL, et al. Oral administration of grape-derived nanovesicles for protection against LPS/D-GalN-induced acute liver failure[J]. Int J Pharm, 2024, 652: 123812. DOI: 10.1016/j.ijpharm.2024.123812.
    [42]
    WANG JL, LIU Y, DING HR, et al. Mesenchymal stem cell-secreted prostaglandin E2 ameliorates acute liver failure via attenuation of cell death and regulation of macrophage polarization[J]. Stem Cell Res Ther, 2021, 12( 1): 15. DOI: 10.1186/s13287-020-02070-2.
    [43]
    XU RX, NI BB, WANG L, et al. CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure[J]. Stem Cell Res Ther, 2022, 13( 1): 55. DOI: 10.1186/s13287-022-02729-y.
    [44]
    YU YP, ZHANG QQ, WU N, et al. HNF4α overexpression enhances the therapeutic potential of umbilical cord mesenchymal stem/stromal cells in mice with acute liver failure[J]. FEBS Lett, 2022, 596( 24): 3176- 3190. DOI: 10.1002/1873-3468.14453.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (717) PDF downloads(27) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return